Subscribe to An active surveillance, post-authorization safety study of serious infection, malignancy, cardiovascular and other safety events of interest among patients treated with tofacitinib for moderately to severely active rheumatoid arthritis within the Spanish registry of adverse events of biological therapies and biosimilars in rheumatoid diseases (BIOBADASER) (Safety of tofacitinib in BIOBADASER)